LAB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

18.50M

-60.4%

-0.025

-49.39%

18.60M

-54.41%

-0.015

-68.62%

20.53M

-5.65%

-0.010

-74.94%

Estimates Revision

The market is revising No Change the revenue expectations for Standard BioTools Inc. (LAB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 13.24%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.76%

In Past 3 Month

Stock Price

Go Up

+13.24%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast LAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LAB is 1.35 USD with a low forecast of 1.35 USD and a high forecast of 1.35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

0 Sell

Hold

Current: 0.000

Low

1.35

Averages

1.35

High

1.35

Current: 0.000

Low

1.35

Averages

1.35

High

1.35

TD Cowen

Hold

downgrade

2025-11-05

Reason

TD Cowen

Price Target

2025-11-05

downgrade

Hold

Reason

TD Cowen lowered the firm's price target on Standard BioTools to $1.35 from $1.55 and keeps a Hold rating on the shares. The firm said there were no surprises in the print with the company now reporting continuing operations revenue post the announced sale of SomaLogic.

TD Cowen

Buy

Hold

downgrade

2025-08-13

Reason

TD Cowen

Price Target

2025-08-13

downgrade

Buy

Hold

Reason

TD Cowen downgraded Standard BioTools to Hold from Buy with a price target of $1.55, down from $1.60, post the Q2 report. The company sees a lower growth outlook for the core business and less visibility following the sale of SomaLogic. The company's core business trends will continue to be challenged amid macro headwinds, the analyst tells investors in a research note.

Keybanc

Paul Knight

Buy

Hold

Downgrades

n/a

2025-02-27

Reason

Keybanc

Paul Knight

Price Target

n/a

2025-02-27

Downgrades

Buy

Hold

Reason

KeyBanc analyst Paul Knight downgraded Standard BioTools to Sector Weight from Overweight without a price target. The company reported preannounced Q4 results with "disappointing" initial 2025 revenue guidance, the analyst tells investors in a research note. The firm says Standard Bio attributed its guidance to the proposed White House National Institutes of Health spending cut that may drive cautious spending for its academic customers. With a "tepid" spending environment and more meaningful commercial revenue from Illumina unlikely to occur until 2026, KeyBanc downgrades the shares.

Valuation Metrics

The current forward P/E ratio for Standard BioTools Inc (LAB.O) is -23.09, compared to its 5-year average forward P/E of -9.67. For a more detailed relative valuation and DCF analysis to assess Standard BioTools Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.67

Current PE

-23.09

Overvalued PE

-3.56

Undervalued PE

-15.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.81

Current EV/EBITDA

-9.88

Overvalued EV/EBITDA

-3.52

Undervalued EV/EBITDA

-12.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.92

Current PS

6.28

Overvalued PS

4.56

Undervalued PS

1.27

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LAB News & Events

Events Timeline

No data

News

9.5

01-08NASDAQ.COM

PinnedStandard BioTools Projects $185 Million Revenue for 2025

9.5

01-08Benzinga

Neogen Corp (NEOG) Reports Q2 Earnings Beat, Shares Surge 28%

8.5

2025-12-31Globenewswire

Labrador Gold Acquires 16.67M Subscription Receipts from Northern Shield for $1M

People Also Watch

Frequently Asked Questions

What is Standard BioTools Inc (LAB) stock price today?

The current price of LAB is 1.54 USD — it has increased 0 % in the last trading day.

What is Standard BioTools Inc (LAB)'s business?

Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.

What is the price predicton of LAB Stock?

What is Standard BioTools Inc (LAB)'s revenue for the last quarter?

Standard BioTools Inc revenue for the last quarter amounts to 19.55M USD, decreased -56.52 % YoY.

What is Standard BioTools Inc (LAB)'s earnings per share (EPS) for the last quarter?

Standard BioTools Inc. EPS for the last quarter amounts to -0.09 USD, increased 28.57 % YoY.

What changes have occurred in the market's expectations for Standard BioTools Inc (LAB)'s fundamentals?

How many employees does Standard BioTools Inc (LAB). have?

Standard BioTools Inc (LAB) has 818 emplpoyees as of January 10 2026.

What is Standard BioTools Inc (LAB) market cap?

Today LAB has the market capitalization of 592.23M USD.